Decision: Favourable

Decisions Table

Study Title:

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

  • NREC Code:

    21-NREC-CT-012

  • Decision:

    Favourable

  • Meeting Date:

    07/07/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Amjad Hayat

  • PI Institution:

    University Hospital Galway

  • Sponsor:

    Incyte Corporation

Scroll to Top